Database

Startups

Main Industry
Biotechnology
Main Product/Service
FormuRx Pharmaceuticals Co., Ltd. focuses on the development of high-barrier lipid nanoparticle formulation technologies, such as dual-action liposomes and LNP (lipid nanoparticle) manufacturing platforms, which are applied in novel drug R&D and nucleic acid drug delivery. The core technology of FormuRx Pharmaceuticals Co., Ltd., the "3-in-1 Formulation Platform," integrates lipid nanocarriers, microfluidic manufacturing processes, and Quality-by-Design (QbD) process design concepts. Committed to its mission of addressing unmet medical needs, the company aims to drive its international commercialization process through technology transfer collaborations and technology licensing.
The content above was translated by Ai
Founded Year
2019
Unified Business No.
85068579
Status
Active
Number of Employees
6
Total Paid-in Capital
33,595,511 (NT$)
Location of Company
Taiwan , Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups. Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed. Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
About the Company
Drawing on decades of experience cultivated by the FormuRx Biotech team in the field of drug research and development, they have observed that startup or small biotechnology and pharmaceutical companies, in order to accelerate profitability or secure the funding required for clinical trials, often ignore or simplify the needs of drug formulation development in the early stages. For instance, they fail to evaluate early on the physicochemical properties of the drug, the compliance and safety of material selection, the clinical route of administration and its subsequent impact on efficacy, and even the mass-producibility of the finished product. These closely linked challenges often lead to setbacks in the clinical trial process, thereby hindering the commercialization of the product and resulting in massive investment losses. If all of these issues could be squarely addressed through the precise optimization of formulations during the initial preclinical trial stage, the massive losses subsequently caused by formulation and recipe issues could be largely avoided. To this end, FormuRx takes "Begin with the End in Mind" as its core corporate philosophy, injecting drug delivery system technology into modern precision therapy to precisely optimize the biopharmaceutical industry value chain. This precision therapy covers the following points to enhance the value of drugs:


The content above was translated by Ai
more ↓

Similar Companies

回頁面最頂端